Sema4 Holdings Corp. (SMFR): Price and Financial Metrics
GET POWR RATINGS... FREE!
SMFR POWR Grades
- Sentiment is the dimension where SMFR ranks best; there it ranks ahead of 65.56% of US stocks.
- SMFR's strongest trending metric is Quality; it's been moving down over the last 138 days.
- SMFR ranks lowest in Quality; there it ranks in the 3rd percentile.
SMFR Stock Summary
- With a one year PEG ratio of 0.43, SEMA4 HOLDINGS CORP is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 4.23% of US stocks.
- With a year-over-year growth in debt of 608.94%, SEMA4 HOLDINGS CORP's debt growth rate surpasses 96.95% of about US stocks.
- SEMA4 HOLDINGS CORP's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -163.12%, greater than the shareholder yield of merely 3.73% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to SEMA4 HOLDINGS CORP are ACTG, FET, TBLT, RMR, and FOUR.
- To check out SEMA4 HOLDINGS CORP's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001818331.
SMFR Valuation Summary
- In comparison to the median Technology stock, SMFR's price/sales ratio is 83.33% lower, now standing at 0.4.
- SMFR's price/sales ratio has moved down 1.9 over the prior 29 months.
Below are key valuation metrics over time for SMFR.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SMFR | 2023-01-06 | 0.4 | 0.2 | -0.3 | 0.1 |
| SMFR | 2023-01-05 | 0.4 | 0.2 | -0.3 | 0.1 |
| SMFR | 2023-01-04 | 0.4 | 0.2 | -0.4 | 0.1 |
| SMFR | 2023-01-03 | 0.5 | 0.2 | -0.4 | 0.1 |
| SMFR | 2022-12-30 | 0.4 | 0.2 | -0.4 | 0.1 |
| SMFR | 2022-12-29 | 0.4 | 0.2 | -0.3 | 0.1 |
SMFR Stock Price Chart Interactive Chart >
SMFR Price/Volume Stats
| Current price | $0.31 | 52-week high | $4.67 |
| Prev. close | $0.25 | 52-week low | $0.22 |
| Day low | $0.25 | Volume | 4,716,400 |
| Day high | $0.33 | Avg. volume | 2,371,220 |
| 50-day MA | $0.53 | Dividend yield | N/A |
| 200-day MA | $1.39 | Market Cap | 117.17M |
Sema4 Holdings Corp. (SMFR) Company Bio
Sema4 Holdings Corp., doing business as Sema4, develops and operates health intelligence software solution that helps in diagnosis, treatment, and prevention of disease. The company offers solutions, such as Sema4, a solution that helps in treatment of the diseases; Centrellis, an analytics platform that generate complete understanding of disease and wellness and extract individualized insights into human health, starting with reproductive health and oncology; Sema4 Signal, a solution that provides data driven care solutions with analytics, digital tools, and exome based somatic and hereditary cancer genomic test; Biopharma, a solution that offers portfolio of health information, pre-clinical and clinical trial support, analytics for actionable insights, and advance sequencing services. It offers noninvasive prenatal select, a blood test for determining baby's health; expanded carrier screen, a carrier screen for more than 280 inherited conditions if one is pregnant or planning for pregnancy; and CarrierCheck, a genetic screen for 67 inherited conditions to know how DNA could affect the children. The company also provides Natalis newborn screen, a home-test to know baby's health by screening for 193 childhood diseases; Solid Tumor panel to analyze cancer driven genes; and test catalogue, a comprehensive offering of genetic and genomic tests. In addition, it owns and operates Centrellis, an analytics platform that generate complete understanding of disease and wellness and extract individualized insights into human health, starting with reproductive health and oncology. The company's solutions include women's health, oncology, expanded carrier screen, noninvasive prenatal select, Natali's newborn screen, hereditary cancer. Sema4 Holdings Corp. is based in Stamford, Connecticut.
Latest SMFR News From Around the Web
Below are the latest news stories about SEMA4 HOLDINGS CORP that investors may wish to consider to help them evaluate SMFR as an investment opportunity.
Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 GuidanceCompany expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis® platforms Company’s common stock will trade on the Nasdaq under new ticker “WGS” effective January 10, 2023 STAMFORD, Conn, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR) today announced it has changed its name from Sema4 Holdings Corp. to GeneDx Holdings Corp. GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clin |
Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare ConferenceSema4|GeneDx President & Chief Executive Officer, Katherine Stueland, to deliver presentationSTAMFORD, Conn., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the company will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco. Katherine Stueland, President and Chief Executive Officer, will deliver a formal presentation on Thursday, January 12, 2023, at 10:30 a.m. PT. A live and archived webcast of the presentation |
New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICUData underscores the value of mitochondrial DNA testing and the opportunity to improve health outcomes for critically ill newborns with early medical interventionSTAMFORD, Conn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the results of a new study on mitochondrial diseases in newborns. The findings support the addition of mitochondrial DNA (mtDNA) testing to rapid exome sequencing, showing it can lead to earlier diagnoses and more immediat |
Sema4 Reports Third Quarter 2022 Financial Results and New Strategic DirectionCompany will focus on its high growth, high margin pediatric and rare disease business, powered by whole exome/genome diagnostic testing and analysis and data-driven insights from Centrellis® 19% pro forma1 volume growth vs. 3Q 2021 and 21% pro forma1 revenue growth vs. 3Q 2021 Sema4 to host a conference call today at 8:30 a.m. ET STAMFORD, Conn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Sema4 Holdings Corp. (Nasdaq: SMFR) (“Sema4”), a health insights company, today announced business highlights and fi |
Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022STAMFORD, Conn., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced it will release financial results for the third quarter of 2022 before the market opens on Monday, November 14, 2022. On the same day, Katherine Stueland, Chief Executive Officer of Sema4, and Kevin Feeley, Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Sema4 will host a con |
SMFR Price Returns
| 1-mo | 27.26% |
| 3-mo | -70.33% |
| 6-mo | -81.55% |
| 1-year | -89.90% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 17.51% |
| 2022 | -94.09% |
| 2021 | -59.60% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...